Drug

JAK2 Inhibitor TQ05105 clinical trials

Also written TQ05105.

studies test it: 17
open now: 4
in phase 3: 0
first study started: 2018

Keep track of what changes. Save the JAK2 Inhibitor TQ05105 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

TQ05105 tablets: 10

Development codes

TQ05105: 5

Studies by the year they started

17 studies that test it; most in 2024 (4)

Studies that test JAK2 Inhibitor TQ05105, by start year
Year	Studies
2018	1
2020	1
2021	3
2022	2
2023	2
2024	4
2026	4

By phase

A phase 1/2 study counts in both.

Phase 1: 14
Phase 2: 7

What it is tested for

Each study’s main condition, where its own words name it.

Primary Myelofibrosis: 10
Bronchiolitis Obliterans Syndrome: 2
Lymphohistiocytosis, Hemophagocytic: 1

Who runs them

Industry 17 · Other 0

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (17)

Often tested with

Tested in the same studies.

Rabeprazole (1) · BET Inhibitor TQB3617 (1)

Studies

Open first, then newest update. How each study uses JAK2 Inhibitor TQ05105 is read from its arms, and is right about nine times in ten.